Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Meng Huang

Neurological Surgery Houston, TX Medical Doctor

NPI 1720347834 CMS profile 213985

6560 Fannin St Ste 900, Houston, TX 77030

Open in the dashboard

General payments

$323,827

438 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Meng Huang of Houston, TX is reported in the CMS Open Payments database as having received $323,827 across 438 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $133,113 134
2024 General $42,089 67
2023 General $40,034 47
2022 General $65,597 49
2021 General $34,343 55
2020 General $2,418 27
2019 General $6,232 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Meng Huang
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Meng Huang were reported at $133,113. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Meng Huang Neurological Surgery median Middle half National median
2019 $6,232 $582 $138–$3,006 $163
2020 $2,418 $294 $76–$2,174 $114
2021 $34,343 $387 $105–$2,432 $132
2022 $65,597 $542 $139–$2,989 $149
2023 $40,034 $534 $145–$2,697 $160
2024 $42,089 $574 $155–$3,046 $164
2025 $133,113 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Joimax, Inc. $114,135 19 payments
  2. Arthrex, Inc. $68,318 67 payments
  3. Orthofix Medical, Inc. $56,851 50 payments
  4. TrackX Technology, LLC $14,778 10 payments
  5. DePuy Synthes Products, Inc. $12,357 14 payments
  6. Spineology Inc. $11,987 6 payments
  7. Integrity Implants Inc $8,861 29 payments
  8. Amplify Surgical, Inc. $8,324 11 payments
  9. Medical Device Business Services, Inc. $6,565 12 payments
  10. Medtronic, Inc. $2,789 43 payments
  11. Other $18,863 177 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $161,408 27 payments
  2. Travel and Lodging $76,491 98 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $59,000 11 payments
  4. Food and Beverage $25,083 295 payments
  5. Entertainment $1,430 6 payments
  6. Education $415 1 payment
Products named General payments · program years 2019–2025
  1. MISCELLANEOUS $25,908 5 payments
  2. Mariner $15,176 1 payment
  3. OPTIMESH EXPANDABLE INTERBODY FUSION SYSTEM $11,600 4 payments
  4. NAVIGATED INSTRUMENTS;PHOENIX SFS $10,119 2 payments
  5. Mongoose $7,305 19 payments
  6. VIPER $3,576 6 payments
  7. Sentio $3,272 3 payments
  8. CONCORDE $3,158 2 payments
  9. COUGAR $3,158 2 payments
  10. Lattus $2,470 21 payments
  11. Other $30,514 256 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

238

Median for Neurosurgery: 83

Drug cost

$2,734

Median for Neurosurgery: $872

Branded share of claims

31.9%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 76 $1,256
Gabapentin Generic 97 $1,058
Methylprednisolone Generic 27 $168
Methocarbamol Generic 11 $129
Tramadol Hcl Generic 27 $123

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$289,808

Medicare's payments for the services billed

Medicare patients

362

Average age 74

Services billed

977

174 women, 188 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 44%
Osteoporosis 37%
Diabetes 33%
Chronic kidney disease 27%
Depression 22%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

438 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record